Heron Therapeutics, Inc. re-affirmed earnings guidance for the full year 2024. For the period, Company expects Net Product Revenues of $138.0 million to $158.0 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.495 USD | +1.84% | -2.70% | +48.24% |
Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.24% | 368M | |
+2.47% | 42.75B | |
+48.09% | 41.61B | |
+12.25% | 41.34B | |
-12.36% | 26.59B | |
+8.09% | 25.49B | |
-22.81% | 18.12B | |
+30.83% | 12.24B | |
-1.85% | 11.76B | |
+7.95% | 11B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024